A First-in-human, Randomized, Double-blind, Placebo Controlled Combined Single-ascending Dose and Multiple-ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BL-1021 in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 May 2014
At a glance
- Drugs BL 1021 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- Sponsors BioLineRx
- 31 Aug 2012 Results presented at the 14th World Congress on Pain.
- 06 Dec 2011 Status changed from active, no longer recruiting to completed, according to a BioLineRx media release.
- 13 Sep 2011 Preliminary results were reported in a BioLineRx media release.